Dihexa vs Substance P

A detailed comparison to help you understand the differences and choose the right peptide for your research goals.

Dihexa

Dihexa is a nootropic peptide derived from angiotensin IV. It has shown remarkable cognitive-enhancing properties in animal studies, being described as potentially millions of times more potent than BDNF.

Full details →

Substance P

Substance P is an 11-amino acid neuropeptide involved in pain transmission, inflammation, and various neurological processes. While not used therapeutically itself, understanding it is crucial for pain research.

Full details →

Side-by-Side Comparison

Aspect	Dihexa	Substance P
Dose Range	5 mg–20 mg	35 mcg–350 mcg
Frequency	1x daily	1x daily
Cycle Length	4–12 weeks	1 weeks
Route	oral	subcutaneous
Mechanism	Acts as a hepatocyte growth factor (HGF) potentiator by binding to its receptor c-Met. Promotes synaptogenesis, neuronal survival, and cognitive enhancement through this pathway.	Binds primarily to NK1 receptors to transmit pain signals from peripheral nerves to the CNS. Also promotes inflammation, causes vasodilation, and stimulates immune cells.
Typical Dosage	Research dosing is highly variable due to extreme potency. Typical range: 10-40mg orally or sublingually. Start with lowest doses due to potency.	Not used as a therapeutic agent. NK1 receptor antagonists (blocking Substance P) are used clinically for chemotherapy-induced nausea.
Administration	Can be taken orally, sublingually, or intranasally. Extremely potent - careful dosing is essential. Best used cyclically.	Research compound only. Therapeutic applications focus on blocking rather than administering Substance P.
Side Effects	Limited human data. Reported effects include headache, temporary brain fog during adjustment, and potential mood changes.	Administration would cause pain, inflammation, and neurogenic responses. Not given therapeutically.
Best For	Cognitive Performance	Cognitive Performance